联合辐射和 ATR 抑制剂治疗后免疫原性细胞死亡由凋亡半胱天冬酶双重调节。
Immunogenic cell death after combined treatment with radiation and ATR inhibitors is dually regulated by apoptotic caspases.
机构信息
Department of Radiation Biology, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
出版信息
Front Immunol. 2023 Jun 6;14:1138920. doi: 10.3389/fimmu.2023.1138920. eCollection 2023.
INTRODUCTION
Inhibitors of the ATR kinase act as radiosensitizers through abrogating the G2 checkpoint and reducing DNA repair. Recent studies suggest that ATR inhibitors can also increase radiation-induced antitumor immunity, but the underlying immunomodulating mechanisms remain poorly understood. Moreover, it is poorly known how such immune effects relate to different death pathways such as caspase-dependent apoptosis. Here we address whether ATR inhibition in combination with irradiation may increase the presentation of hallmark factors of immunogenic cell death (ICD), and to what extent caspase activation regulates this response.
METHODS
Human lung cancer and osteosarcoma cell lines (SW900, H1975, H460, U2OS) were treated with X-rays and ATR inhibitors (VE822; AZD6738) in the absence and presence of a pan-caspase inhibitor. The ICD hallmarks HMGB1 release, ATP secretion and calreticulin surface-presentation were assessed by immunoblotting of growth medium, the assay and an optimized live-cell flow cytometry assay, respectively. To obtain accurate measurement of small differences in the calreticulin signal by flow cytometry, we included normalization to a barcoded control sample.
RESULTS
Extracellular release of HMGB1 was increased in all the cell lines at 72 hours after the combined treatment with radiation and ATR inhibitors, relative to mock treatment or cells treated with radiation alone. The HMGB1 release correlated largely - but not strictly - with loss of plasma membrane integrity, and was suppressed by addition of the caspase inhibitor. However, one cell line showed HMGB1 release despite caspase inhibition, and in this cell line caspase inhibition induced pMLKL, a marker for necroptosis. ATP secretion occurred already at 48 hours after the co-treatment and did clearly not correlate with loss of plasma membrane integrity. Addition of pan-caspase inhibition further increased the ATP secretion. Surface-presentation of calreticulin was increased at 24-72 hours after irradiation, but not further increased by either ATR or caspase inhibition.
CONCLUSION
These results show that ATR inhibition can increase the presentation of two out of three ICD hallmark factors from irradiated human cancer cells. Moreover, caspase activation distinctly affects each of the hallmark factors, and therefore likely plays a dual role in tumor immunogenicity by promoting both immunostimulatory and -suppressive effects.
简介
ATR 激酶抑制剂通过阻断 G2 检查点和减少 DNA 修复,充当放射增敏剂。最近的研究表明,ATR 抑制剂还可以增加辐射诱导的抗肿瘤免疫,但潜在的免疫调节机制仍知之甚少。此外,人们对这种免疫效应与细胞凋亡等不同的死亡途径有何关系知之甚少。在这里,我们研究了 ATR 抑制与照射相结合是否会增加免疫原性细胞死亡 (ICD) 的标志性因素的呈现,以及 caspase 激活在多大程度上调节这种反应。
方法
用人肺癌和骨肉瘤细胞系(SW900、H1975、H460、U2OS)用 X 射线和 ATR 抑制剂(VE822;AZD6738)处理,不使用和存在泛半胱天冬酶抑制剂。通过生长培养基的免疫印迹、测定和优化的活细胞流式细胞术测定,分别评估 ICD 标志物 HMGB1 释放、ATP 分泌和钙网蛋白表面呈现。为了通过流式细胞术准确测量 calreticulin 信号的微小差异,我们包括了对条形码对照样品的归一化。
结果
与模拟处理或单独用辐射处理的细胞相比,在联合用辐射和 ATR 抑制剂处理后 72 小时,所有细胞系的细胞外 HMGB1 释放均增加。HMGB1 释放在很大程度上 - 但并非严格 - 与质膜完整性的丧失相关,并且被半胱天冬酶抑制剂抑制。然而,一个细胞系尽管存在半胱天冬酶抑制剂仍释放 HMGB1,并且在该细胞系中,半胱天冬酶抑制剂诱导了 pMLKL,这是一种坏死性凋亡的标志物。ATP 分泌在联合处理后 48 小时就已经发生,并且与质膜完整性的丧失没有明显相关性。加入泛半胱天冬酶抑制剂进一步增加了 ATP 分泌。钙网蛋白的表面呈现从照射后的 24-72 小时增加,但 ATR 或半胱天冬酶抑制均未进一步增加。
结论
这些结果表明,ATR 抑制可增加来自照射的人癌细胞中三个 ICD 标志性因素中的两个的呈现。此外,半胱天冬酶的激活明显影响每个标志性因素,因此通过促进免疫刺激和 - 抑制作用,可能在肿瘤免疫原性中发挥双重作用。